Search

Your search keyword '"Heine, R. Phillips"' showing total 275 results
Start Over Author "Heine, R. Phillips" Publication Year Range Last 50 years
275 results on '"Heine, R. Phillips"'

4. Alliance for Innovation on Maternal Health

Author

Bauer, Melissa E., primary, Albright, Catherine, additional, Prabhu, Malavika, additional, Heine, R. Phillips, additional, Lennox, Chelsea, additional, Allen, Christie, additional, Burke, Carol, additional, Chavez, April, additional, Hughes, Brenna L., additional, Kendig, Susan, additional, Le Boeuf, Maile, additional, Main, Elliott, additional, Messerall, Tiffany, additional, Pacheco, Luis D., additional, Riley, Laura, additional, Solnick, Rachel, additional, Youmans, Andrew, additional, and Gibbs, Ronald, additional

Published
2023
Full Text
View/download PDF

5. Designing Drug Trials: Considerations for Pregnant Women

Author

Sheffield, Jeanne S, Siegel, David, Mirochnick, Mark, Heine, R Phillips, Nguyen, Christine, Bergman, Kimberly L, Savic, Rada M, Long, Jill, Dooley, Kelly E, and Nesin, Mirjana

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Pediatric, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Orphan Drug, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Reproductive health and childbirth, Good Health and Well Being, Adult, Clinical Protocols, Clinical Trials as Topic, Female, Humans, Infant, Maternal-Fetal Exchange, Pharmacokinetics, Placenta, Pregnancy, Pregnancy Outcome, Pregnant Women, Research Design, United States, United States Food and Drug Administration, pregnancy, drug trials, pharmacokinetics, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

Clinical pharmacology studies that describe the pharmacokinetics and pharmacodynamics of drugs in pregnant women are critical for informing on the safe and effective use of drugs during pregnancy. That being said, multiple factors have hindered the ability to study drugs in pregnant patients. These include concerns for maternal and fetal safety, ethical considerations, the difficulty in designing appropriate trials to assess the study objectives, and funding limitations. This document summarizes the recommendations of a panel of experts convened by the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. These experts were charged with reviewing the issues related to the development of preclinical and clinical drug studies in pregnant women and to develop strategies for addressing these issues. These findings may also be utilized in the development of future drug studies involving pregnant women and their fetus/neonate.

Published
2014

28. Characterization of progesterone receptor isoform expression in fetal membranes

Author

Mills, Alyssa A., Yonish, Bryan, Feng, Liping, Schomberg, David W., Heine, R. Phillips, and Murtha, Amy P.

Subjects
Messenger RNA, Progesterone, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajog.2006.06.040 Byline: Alyssa A. Mills (a), Bryan Yonish (a), Liping Feng (a), David W. Schomberg (a)(b), R. Phillips Heine (a), Amy P. Murtha (a) Abstract: To quantify expression of progesterone receptor (PR) messenger RNA (mRNA) isoforms in fetal membranes, and to determine whether these levels change in culture. Author Affiliation: (a) Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine (b) Department of Cell Biology, Duke University Medical Center, Durham, NC Article History: Received 10 March 2006; Revised 6 June 2006; Accepted 10 June 2006 Article Note: (footnote) Presented at the 26th Annual Meeting of the Society for Maternal Fetal Medicine, January 30 to February 4, 2006, Miami, FL. Reprints not available from the authors.

Published
2006

31. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment

Author

MacPherson, Cora A., Klebanoff, Mark A, Hauth, John C., Wapner, Ronald J., Carey, J. Christopher, Heine, R. Phillips, Iams, Jay D., Moawad, Atef, Sibai, Baha M., Miodovnik, Menachem, vanDorsten, J. Peter, and Dombrowski, Mitchell P.

Subjects
Vaginosis -- Care and treatment, Vaginosis -- Research, Metronidazole -- Research, Lactobacillus -- Research, Health
Abstract

A study is conducted on 658 women with asymptomatic bacterial vaginosis to determine the time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment and the probability of spontaneous resolution with placebo. Women undergoing placebo treatment had a significant remission of bacterial vaginosis over ten weeks and the remission is more common when the initial vaginal microbiologic disturbance is less.

Published
2004

33. Bacterial vaginosis and vaginal fluid defensins during pregnancy

Author

Balu, Rukmini B., Savitz, David A., Ananth, Cande V., Hartmann, Katherine E., Miller, William C., Thorp, John M., and Heine, R. Phillips

Subjects
Vaginosis -- Physiological aspects, Animal defenses, Health
Abstract

The amount of defensins in vaginal fluid increases during bacterial vaginosis, according to a study of 749 pregnant women. Bacterial vaginosis is a bacterial infection in the vagina. If it travels up into the uterus, it can cause premature birth. Defensins are natural substances produced by the body to fight infection.

Published
2002

37. Placenta Accreta Spectrum

Author

Cahill, Alison G., primary, Beigi, Richard, additional, Heine, R. Phillips, additional, Silver, Robert M., additional, and Wax, Joseph R., additional

Published
2018
Full Text
View/download PDF

38. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women

Author

Fortner, Kimberly B., primary, Swamy, Geeta K., additional, Broder, Karen R., additional, Jimenez-Truque, Natalia, additional, Zhu, Yuwei, additional, Moro, Pedro L., additional, Liang, Jennifer, additional, Walter, Emmanuel B., additional, Heine, R. Phillips, additional, Moody, M. Anthony, additional, Yoder, Sandra, additional, and Edwards, Kathryn M., additional

Published
2018
Full Text
View/download PDF

46. Placenta Accreta Spectrum.

Author

Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, Cahill, Alison G, Beigi, Richard, Heine, R Phillips, Silver, Robert M, and Wax, Joseph R

Abstract

Placenta accreta spectrum, formerly known as morbidly adherent placenta, refers to the range of pathologic adherence of the placenta, including placenta increta, placenta percreta, and placenta accreta. The most favored hypothesis regarding the etiology of placenta accreta spectrum is that a defect of the endometrial-myometrial interface leads to a failure of normal decidualization in the area of a uterine scar, which allows abnormally deep placental anchoring villi and trophoblast infiltration. Maternal morbidity and mortality can occur because of severe and sometimes life-threatening hemorrhage, which often requires blood transfusion. Although ultrasound evaluation is important, the absence of ultrasound findings does not preclude a diagnosis of placenta accreta spectrum; thus, clinical risk factors remain equally important as predictors of placenta accreta spectrum by ultrasound findings. There are several risk factors for placenta accreta spectrum. The most common is a previous cesarean delivery, with the incidence of placenta accreta spectrum increasing with the number of prior cesarean deliveries. Antenatal diagnosis of placenta accreta spectrum is highly desirable because outcomes are optimized when delivery occurs at a level III or IV maternal care facility before the onset of labor or bleeding and with avoidance of placental disruption. The most generally accepted approach to placenta accreta spectrum is cesarean hysterectomy with the placenta left in situ after delivery of the fetus (attempts at placental removal are associated with significant risk of hemorrhage). Optimal management involves a standardized approach with a comprehensive multidisciplinary care team accustomed to management of placenta accreta spectrum. In addition, established infrastructure and strong nursing leadership accustomed to managing high-level postpartum hemorrhage should be in place, and access to a blood bank capable of employing massive transfusion protocols should help guide decisions about delivery location. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results